NOVO.B.DK

465

-3.86%↓

COLO.B.DK

700.6

-3.97%↓

ZEAL.DK

451.8

-7.38%↓

HLUNB.DK

31.62

-8.67%↓

AMBUB.DK

114.2

-4.52%↓

NOVO.B.DK

465

-3.86%↓

COLO.B.DK

700.6

-3.97%↓

ZEAL.DK

451.8

-7.38%↓

HLUNB.DK

31.62

-8.67%↓

AMBUB.DK

114.2

-4.52%↓

NOVO.B.DK

465

-3.86%↓

COLO.B.DK

700.6

-3.97%↓

ZEAL.DK

451.8

-7.38%↓

HLUNB.DK

31.62

-8.67%↓

AMBUB.DK

114.2

-4.52%↓

NOVO.B.DK

465

-3.86%↓

COLO.B.DK

700.6

-3.97%↓

ZEAL.DK

451.8

-7.38%↓

HLUNB.DK

31.62

-8.67%↓

AMBUB.DK

114.2

-4.52%↓

NOVO.B.DK

465

-3.86%↓

COLO.B.DK

700.6

-3.97%↓

ZEAL.DK

451.8

-7.38%↓

HLUNB.DK

31.62

-8.67%↓

AMBUB.DK

114.2

-4.52%↓

Search

Genmab A-S

Avatud

1,282 -1.99

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1268.5

Max

1324.5

Põhinäitajad

By Trading Economics

Sissetulek

2.1B

3.8B

Müük

901M

6.4B

P/E

Sektori keskmine

10.917

73.239

Aktsiakasum

60.121

Kasumimarginaal

59.696

Töötajad

2,682

EBITDA

-297M

1.8B

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

-1.49% downside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

1. mai 2025

Turustatistika

By TradingEconomics

Turukapital

-3.8B

87B

Eelmine avamishind

1283.99

Eelmine sulgemishind

1282

Genmab A-S Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. märts 2025, 15:16 UTC

Suurimad hinnamuutused turgudel

Genmab Shares Fall After J&J Drops Blood-Cancer Treatment Option

3. apr 2024, 13:04 UTC

Omandamised, ülevõtmised, äriostud

Correction to Genmab Article

3. apr 2024, 08:08 UTC

Omandamised, ülevõtmised, äriostud

Genmab Strengthens Oncology Portfolio With $1.8 Billion Acquisition of ProfoundBio

10. dets 2024, 07:05 UTC

Market Talk

EU Specialty Pharma to See Product Launches But Limited Clinical Data Next Year -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Genmab A-S Prognoos

Hinnasiht

By TipRanks

-1.49% langus

12 kuu keskmine prognoos

Keskmine 2,493.35 DKK  -1.49%

Kõrge 3,320 DKK

Madal 308.417 DKK

Põhineb 7 Wall Streeti analüütiku instrumendi Genmab A-S 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

7 ratings

3

Osta

2

Hoia

2

Müü

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Genmab A-S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.